Publication:
Depression and Cognitive Impairment in a Spanish Sample of Psychoactive Substance Users Receiving Mental Health Care.

dc.contributor.authorLuque, Barbara
dc.contributor.authorGarcia, Victoriana
dc.contributor.authorTabernero, Carmen
dc.contributor.funderSpanish Ministry of Science, Innovation and Universities
dc.date.accessioned2023-05-03T13:54:23Z
dc.date.available2023-05-03T13:54:23Z
dc.date.issued2022-05-09
dc.description.abstract(1) Background: Numerous studies state that the abuse of psychoactive substances produces cognitive, emotional and behavioral disorders. The aim of this study is to analyze the relationship between the consumption of different psychoactive substances with cognitive performance and depression. (2) Methods: The sample was composed of 254 individuals (M = 41.81; SD = 10.74, from 18 to 69; 76% male) who received psychological treatment related to the use of substances. Participants were classified according to the main substance consumed: alcohol (42.9%), cannabis (20.5%), cocaine (15.4%), heroin (13%) and benzodiazepines (8.3%). The Montreal Cognitive Assessment and the Beck's Depression Inventory were administrated. (3) The results indicated no statistically significant differences between levels of depression depending on the substance consumed. Regarding cognitive impairment, it was found that cocaine consumers have the worst level of cognitive impairment, while cannabis consumers have the best level of cognitive functioning. Finally, it was found that participants with severe depression have higher cognitive impairment than those who were diagnosed with moderate depression. (4) Conclusions: Given the high prevalence of depression and cognitive impairment with the abuse of psychoactive substances, early treatment is recommended to avoid a higher cognitive and emotional affectation.
dc.description.versionSi
dc.identifier.citationLuque B, García V, Tabernero C. Depression and Cognitive Impairment in a Spanish Sample of Psychoactive Substance Users Receiving Mental Health Care. Healthcare (Basel). 2022 May 11;10(5):887
dc.identifier.doi10.3390/healthcare10050887
dc.identifier.issn2227-9032
dc.identifier.pmcPMC9141869
dc.identifier.pmid35628023
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141869/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2227-9032/10/5/887/pdf?version=1652756553
dc.identifier.urihttp://hdl.handle.net/10668/20994
dc.issue.number5
dc.journal.titleHealthcare (Basel, Switzerland)
dc.language.isoen
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.page.number10
dc.provenanceRealizada la curación de contenido 22/08/2024
dc.publisherMDPI
dc.pubmedtypeJournal Article
dc.relation.projectIDPDI2019-107304RB-I00
dc.relation.publisherversionhttps://www.mdpi.com/2227-9032/10/5/887
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAlcohol
dc.subjectCocaine
dc.subjectCognitive impairment
dc.subjectDepression
dc.subjectPsychoactive substances
dc.subject.decsAlucinógenos
dc.subject.decsCognición
dc.subject.decsDisfunción cognitiva
dc.subject.decsHeroína
dc.subject.decsPruebas de estado mental y demencia
dc.subject.decsTrastorno depresivo mayor
dc.subject.meshCannabis
dc.subject.meshHeroin
dc.subject.meshDepressive disorder, major
dc.subject.meshCognitive dysfunction
dc.subject.meshHallucinogens
dc.subject.meshCognition
dc.subject.meshMental status and dementia tests
dc.titleDepression and Cognitive Impairment in a Spanish Sample of Psychoactive Substance Users Receiving Mental Health Care.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9141869.pdf
Size:
795.96 KB
Format:
Adobe Portable Document Format